Based on these two assays, we selected samples from four AD patients with the highest concentrations of tau aggregates and from four CTL samples to constitute a pooled AD‐tau mix and a CTL‐tau mix (Figure 1C). This evidence concerns the gene MAPT and Alzheimer disease.